Nanobiotix Secures Up to $71 Million in Royalty Financing from HealthCare Royalty
I'm PortAI, I can summarize articles.
Nanobiotix SA has secured up to $71 million in non-dilutive financing through a royalty monetization agreement with Healthcare Royalty (HCRx). The deal includes an upfront payment of $50 million, with an additional $21 million expected after one year, contingent on certain conditions. The funding will support the advancement of Nanobiotix’s nanotherapeutics platforms and extend its cash runway into early 2028, particularly for head and neck and lung cancer developments. HCRx will receive a capped portion of milestones and royalties on sales of JNJ-1900 (NBTXR3). TD Cowen acted as the financial advisor.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments